Cannovum is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. We focus on the import of medical cannabis, medical-scientific education and distribution for facilitated access to cannabis-based therapies.
Every patient deserves the best therapy. Medical cannabis can be a significant part of that therapy. Cannovum actively promotes access to cannabis for every patient that this form of therapy could help. As pioneers of the European cannabis revolution, the well-being of patients is our top priority.
Our Medical Advisory Board consists of experts and pioneers in cannabis therapy. The members of our board advise us with their scientific expertise and longterm practical experience. Head of the Medical Advisory Board is Dr. med. Dipl.-Chem. Konrad F. Cimander.
Dr. med. Dipl.-Chem. Konrad F. Cimander is an expert in addiction medicine, infectiology and cannabis therapy. He studied chemistry and human medicine at the WWU in Münster and received his doctorate in hand and accident surgery. After years of research in the pharmaceutical industry and development of new psychoactive medications, he founded the Competence Center for Addiction Medicine and Cannabis Therapy in 1993, which he still leads today.
In addition to his former work as a university teacher for general medicine at the Hannover Medical School and the medical faculty of the University of Göttingen in the field of addiction, psychopharmacology, and prevention, Dr. Cimander is chairman and member of many medical associations.
In 2020 he took over the scientific lead of the first Medicinal Cannabis Congress in Berlin and will once again do so in 2021. Especially important to him are scientific investigation and clarification of medical questions concerning the patients' well-being.
Dr. Cimander consults Cannovum as 'Chief Medical Advisor'.
Priv. Doz. Dr. med. habil. Philipp Sewerin has extensive scientific expertise in the field of internal medicine and rheumatology. After studying human medicine at the Heinrich-Heine-University Düsseldorf and the UZH Zurich, he obtained his habilitation in the field of inflammatory-rheumatic joint diseases. Since 2017, he has continued his career as a specialist in internal medicine and rheumatology at the University Hospital in Düsseldorf. In addition, he is currently active in clinical research, focused on inflammatory rheumatic diseases. His roles involve leading both the clinical trials and imaging department of rheumatology.
Dr. Sewerin is very committed to the well-being of patients and is a member of various associations and organizations, such as the German Society for Internal Medicine, the German Society for Rheumatology and the advisory board of the Rheumatism Academy. He has already received several awards for his achievements, most recently from the F.A.Z. Institute for special achievements in the COVID-19 Pandemic 2020.
Dr. Dennis Stracke is an expert in medicinal cannabis and a renowned pharmacist. After studying pharmacy and earning his doctorate at the Institute for Physiological Chemistry and Pathobiochemistry in Münster, he began working as a pharmacist. Since June 2010, Dr. Stracke has been a pharmacist at MediosApotheke in Berlin and heads the department of neurology and rare diseases. His focus is particularly on neuromuscular, neuroimmunological, neurodegenerative and neuro-oncological diseases. Dr. Stracke is deeply committed to providing more patients with access to cannabis-based therapies. To achieve this, Dr. Stracke assists physicians, pharmacists, and medical assistants in expanding their knowledge base on medical cannabis and potential therapeutic approaches, including teaching courses at the University of Dresden. Dr. Stracke will advise Cannovum AG with his specific pharmacological expertise and enrich Cannovum Medical Education.
Sandra has 15 years of experience in the healthcare industry and expertise in marketing. After completing her PhD at the Charité in Berlin, she advised biotech and pharma companies with market entry in Germany. Most recently, she led the medical affairs department and built an educational platform for a Canadian cannabis manufacturer.Since cannabis as medicine is rarely part of pharmaceutical and medical education, she is particularly passionate about spreading more knowledge about the medical-therapeutic use of cannabis. At Cannovum, she takes care of marketing and medical education, and gives customized, free workshops to healthcare professionals.
CEO & Co-Founder
Pia is the Chief Executive Officer of Cannovum AG. Prior to founding Cannovum, she led the company management in the renewable energy sector. This gave her not only the opportunity to strengthen her expertise on how to run operational businesses, but also to develop the implementation of resource-saving approaches. Pia’s aim is to fully harness the potential of the cannabis plant and provide patients in Germany and Europe with medical cannabis that is sunlight ripened, free of chemical pesticides and sustainably grown.
Co-Founder
Marius is Co-Founder of Cannovum AG and has years of pharmaceutical experience. He worked for 13 years in various roles in the pharmaceutical industry, mostly with an international focus. Most recently, he developed new processes and systems in California and Germany as a project manager for the pharmaceutical company Bayer in the field of biological development. Marius incorporates his expertise in pharmaceutical market advancement into developing Cannovum’s cannabis-based medicines to provide the best therapy for each patient.
Head of Quality Assurance
Timo holds a PhD in Inorganic Chemistry from Bielefeld University. Advocating for the well-being of patients and improving their care have accompanied him for a long time. Alongside his studies, he began volunteering with DKMS to find bone marrow donors for leukemia patients. Timo is actively committed to realizing the full potential of cannabis-based therapies. Together with other scientists at Bielefeld University, he conducted research on smart microgel particles as a delivery system for cannabinoids, among other things. His expertise in cannabinoid research informs his work at Cannovum as Head of Quality Assurance. He is responsible for the extraordinary quality of our products.
Chairman Supervisory Board
Udo spent around 40 years in the IT and telecommunications (ICT) industry. He started his career at IBM, the International Business Machines Corporation. Afterwards he led the companies WANG, Data General and Nortel Networks in the DACH organization to extraordinary success as managing director. Today, he advises medium-sized companies as a business consultant in the area of corporate development and strategic planning. He supports Cannovum AG as chairman of the supervisory board.
Head of Sales
Paul spent the last 22 years in various functions and roles at one of the world’s largest pharmaceutical companies. His main area of expertise lies in sales and distribution. Paul is well-versed in the medical cannabis market, having previously gained experience in the field through other cannabis companies. Paul is dedicated to bringing his years of experience to ensure that every patient gets the best cannabis-based therapy.
CMO
Klaus has worked as a journalist, editor-in-chief and content director in various positions in Germany and Europe over the past 20 years. After starting as an editor at the news magazine DER SPIEGEL, he held positions at the media houses Conde Nast, Burda and Handelsblatt. Thanks to his many years of consulting work for Wort und Bild Verlag, Klaus is very familiar with the digitization of the healthcare system.
© 2022 Cannovum AG. All rights reserved.
